The impact of addiction on individuals, families, and society is profound and complex. Substance abuse and addiction are global health challenges. The World Health Organization…
View More Human-centered approaches key to addiction treatment
“If we meet these goals, investors could expect ~15% annualized returns over the next six years,” the management stated. However, they acknowledged that reaching more than triple the current EBITDA could be a “tough ask.”
View More Piramal Pharma sets bold growth targets for 2030
The event, inaugurated by Jitin Prasada, Union Minister of State for Commerce and Industry, gathered industry leaders, regulatory officials, and experts to discuss advancements in the pharmaceutical sector.
View More Serum Institute fast-tracks monkeypox vaccine: ‘Initial studies by end of year’ says Mulay
Highlighting the significance of innovative technologies in the biomedical field, Dr. Srinivas stated that AIIMS is committed to collaborating with academic and research institutions, particularly CSIR. He commended CSIR-NIIST Director Dr. C. Anandharamakrishnan and his team for offering an alternative solution for the disposal of pathogenic biomedical waste.
View More CSIR-NIIST develops tech for biomedical waste disposal
Bharat Biotech International Limited (BBIL), a global leader in vaccine innovation and developer of vaccines for infectious diseases, on Wednesday announced its rotavirus oral vaccine ROTAVAC® has been introduced by Nigeria to immunize its children
View More Nigeria Rolls Out Bharat Biotech’s ROTAVAC Vaccine For Immunization
BENGALURU: India’s top biopharmaceutical company, Biocon Biologics, on Tuesday rubbished the allegations that they paid kickbacks to the tune of Rs 4 lakh to Joint…
View More Bound By Code Of Conduct: Biocon Refutes Bribery Allegations
NEW DELHI: Bharat Biotech’s Covaxin has proven to be ‘safe, well-tolerated, and highly immunogenic’ in children in Phase II/III studies, the results of which are…
View More Covaxin Safe, Highly Immunogenic In Children, Says Study